FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Web Exclusives —March 15, 2019
Yvette Florio Lane

On March 8, 2019, the FDA granted accelerated approval to Genentech’s Tecentriq (atezolizumab), in combination with nab-paclitaxel (Abraxane), for the treatment of PD-L1–positive unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). This marks the first time an immunotherapy drug has been granted approval for the treatment of any form of breast cancer.

This indication was granted accelerated approval based on data from the phase 3 IMpassion130 study, a multicenter, international, double-blind, placebo-controlled, randomized trial of 902 patients with unresectable locally advanced or metastatic TNBC who had not received prior chemotherapy for metastatic disease. In this study, the median progression-free survival for patients with PD-L1–positive tumors treated with atezolizumab plus nab-paclitaxel was 7.4 months versus 4.8 months for those treated with nab-paclitaxel plus placebo.

The most common side effects (reported in ≥20% of patients) were hair loss, fatigue, numbness or tingling in the hands and feet, nausea, diarrhea, low red blood cell count, constipation, cough, headache, low white blood cell count, decreased appetite, and vomiting.

This is the fifth approval for the PD-L1 inhibitor Tecentriq, which has been approved for use in the treatment of some forms of lung cancer, bladder cancer, and urothelial cancers.

Breast cancer is the most common female cancer worldwide. According to the American Cancer Society, approximately 271,000 people in the United States will be diagnosed with breast cancer in 2019. Of those, approximately 15% will be diagnosed with TNBC, an aggressive form of the disease with few treatment options.

The FDA’s Accelerated Approval Program allows conditional approval of a medicine that fills an unmet medical need for a serious or life-threatening disease or condition. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Related Articles
Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer
Yvette Florio Lane
|
Web Exclusives
Lung cancer is the second most frequently diagnosed malignancy in both men and women (following prostate and breast cancer, respectively), and the leading cause of cancer deaths overall. Non–small-cell lung cancer (NSCLC) is the most common type, with the more aggressive small-cell lung cancer (SCLC) making up approximately 10% to 15% of cases.
Welcome to the Fourth Annual Oncology Guide to New FDA Approvals
2019 Fourth Annual Oncology Guide to New FDA Approvals
The Lynx Group is pleased to bring you the Fourth Annual Oncology Guide to New FDA Approvals. The goal of this Guide is to offer oncologists, pharmacists, oncology nurses, and other healthcare stakeholders a comprehensive overview of new drugs approved by the US Food and Drug administration (FDA) in 2018 for the treatment of different types of cancer, including hematologic and oncologic malignancies. This practical tool offers a quick, evidence-based resource for hematology/oncology professionals to guide their medication-related decision-making and help ensure the administration of recent medicines for appropriate patients.
New Indications Approved by the FDA in 2018 for Oncology Drugs
Dalia Buffery, MA, ABD
|
2019 Fourth Annual Oncology Guide to New FDA Approvals
  • Introduction
  • Oncology Overview
  • Breast Cancer New Indications
  • Genitourinary Cancers New Indications
  • Gynecologic Cancers New Indications
  • Hematologic Malignancies New Indications
  • Lung Cancer New Indications
  • Other Tumor Types New Indications
Last modified: March 22, 2019

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code